Income Statement Guizhou Bailing Group Pharmaceutical Co., Ltd.

Cash And Equivalents

Accounts Receivable, Total

Other Receivables

Inventory

Other Current Assets, Total

Gross Property Plant And Equipment

Accumulated Depreciation

Long-term Investments

Goodwill

Other Intangibles, Total

Deferred Tax Assets Long-Term

Deferred Charges Long-Term

Other Long-Term Assets, Total

Accounts Payable, Total

Accrued Expenses, Total

Short-term Borrowings

Current Portion of Long-Term Debt

Current Portion of Leases

Current Income Taxes Payable

Unearned Revenue Current, Total

Other Current Liabilities

Long-Term Debt

Long-Term Leases

Unearned Revenue Non Current

Deferred Tax Liability Non Current

Other Non Current Liabilities

Common Stock, Total

Additional Paid In Capital

Retained Earnings

Treasury Stock

Comprehensive Income and Other

Total Common Equity

Minority Interest

ECS Total Shares Outstanding on Filing Date

ECS Total Common Shares Outstanding

Book Value / Share

Tangible Book Value

Tangible Book Value Per Share

Total Debt

Net Debt

Debt Equivalent Oper. Leases

Minority Interest, Total (Incl. Fin. Div)

Equity Method Investments, Total

Account Code - Inventory Valuation

Inventories - Raw Materials, Total

Inventories - Work In Process, Total

Inventories - Finished Goods, Total

Buildings, Total

Machinery, Total

Full Time Employees

Accumulated Allowance for Doubtful Accounts (Supple)

Net Income

Depreciation & Amortization - CF

Amortization of Goodwill and Intangible Assets - (CF)

Depreciation & Amortization, Total

Amortization of Deferred Charges, Total - (CF)

(Gain) Loss From Sale Of Asset

(Gain) Loss on Sale of Investments - (CF)

Asset Writedown & Restructuring Costs

Provision and Write-off of Bad Debts

Other Operating Activities, Total

Change In Accounts Receivable

Change In Inventories

Change In Accounts Payable

Change In Deferred Taxes

Change in Other Net Operating Assets

Capital Expenditure

Sale of Property, Plant, and Equipment

Cash Acquisitions

Divestitures

Investment in Marketable and Equity Securities, Total

Net (Increase) Decrease in Loans Originated / Sold - Investing

Other Investing Activities, Total

Short Term Debt Issued, Total

Long-Term Debt Issued, Total

Total Debt Issued

Short Term Debt Repaid, Total

Long-Term Debt Repaid, Total

Total Debt Repaid

Issuance of Common Stock

Repurchase of Common Stock

Common Dividends Paid

Common & Preferred Stock Dividends Paid

Other Financing Activities, Total

Foreign Exchange Rate Adjustments

Cash Income Tax Paid (Refund)

Change In Net Working Capital

Net Debt Issued / Repaid

Return on Assets

Return on Total Capital

Return On Equity %

Return on Common Equity

Gross Profit Margin %

SG&A Margin

EBITDA Margin %

EBITA Margin %

EBIT Margin %

Income From Continuing Operations Margin %

Net Income Margin %

Net Avail. For Common Margin %

Normalized Net Income Margin

Levered Free Cash Flow Margin

Unlevered Free Cash Flow Margin

Asset Turnover

Fixed Assets Turnover

Receivables Turnover (Average Receivables)

Inventory Turnover (Average Inventory)

Current Ratio

Quick Ratio

Operating Cash Flow to Current Liabilities

Days Sales Outstanding (Average Receivables)

Days Outstanding Inventory (Average Inventory)

Average Days Payable Outstanding

Cash Conversion Cycle (Average Days)

Total Debt/Equity

Total Debt / Total Capital

LT Debt/Equity

Long-Term Debt / Total Capital

Total Liabilities / Total Assets

EBIT / Interest Expense

EBITDA / Interest Expense

(EBITDA - Capex) / Interest Expense

Total Debt / EBITDA

Net Debt / EBITDA

Total Debt / (EBITDA - Capex)

Net Debt / (EBITDA - Capex)

Total Revenues, 1 Yr. Growth %

Gross Profit, 1 Yr. Growth %

EBITDA, 1 Yr. Growth %

EBITA, 1 Yr. Growth %

EBIT, 1 Yr. Growth %

Earnings From Cont. Operations, 1 Yr. Growth %

Net Income, 1 Yr. Growth %

Normalized Net Income, 1 Yr. Growth %

Diluted EPS Before Extra, 1 Yr. Growth %

Accounts Receivable, 1 Yr. Growth %

Inventory, 1 Yr. Growth %